24th Jun 2016 09:45
Abzena plc
("Abzena", the "Company" or the "Group")
Exercise of warrants
Cambridge, UK, 24 June 2016 ‐ Abzena plc (AIM: ABZA) announces that 81,250 new ordinary shares of £0.002 each in the Company (the "Ordinary Shares") have been issued and allotted following the exercise of warrants.
The new Ordinary Shares rank pari passu with the Company's existing issued ordinary shares. Application will be made for admission to trading on AIM and it is expected that admission will occur on 29 June 2016.
Following Admission, the Company's enlarged issued share capital will comprise 137,055,555 ordinary shares with voting rights. No shares are held in Treasury. The total number of voting rights in the Company is therefore 137,055,555. This figure of 137,055,555 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For more information, please contact:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer
| +44 1223 903498 |
Cenkos Securities (Nominated Adviser and Broker) Christopher Golden / Ivonne Cantu | +44 20 7397 8900 |
N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong | +44 20 7496 3000 |
Instinctif Partners Melanie-Toyne Sewell / Rozi Morris | +44 20 7457 2020 |
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ antibody drug conjugates. Abzena has the potential to earn future licence fees, milestone payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
§ Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
§ Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
§ Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.
§ Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.
For more information, please see www.abzena.com
Related Shares:
Abzena